In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
about
KASL clinical practice guidelines: management of chronic hepatitis BThe Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide AnalogsStable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B VirusEfficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.Complex dynamics of hepatitis B virus resistance to adefovir.Effect and mechanism of beta-L-D4A on DNA polymerase alphaComparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysisLong-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.New approaches in the management of chronic hepatitis B: role of tenofovir.Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective studyCurrent Antiviral Therapy of Chronic Hepatitis B: Efficacy and SafetyHigh efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovirKASL Clinical Practice Guidelines: Management of chronic hepatitis B.Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failuresAntiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants aloneReview of tenofovir-emtricitabine.Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Efficacies of beta-L-D4A against Hepatitis B virus in 2.2.15 cells.Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.Antiviral resistance and hepatitis B therapy.Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure.Management of Antiviral Resistance in Chronic Hepatitis B.Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?Molecular diagnosis and treatment of drug-resistant hepatitis B virus.Management of antiviral drug resistance in chronic hepatitis BNonpolar nucleoside mimics as active substrates for human thymidine kinases.Tenofovir and its potential in the treatment of hepatitis B virus.Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis
P2860
Q26752475-BD386DE3-AC47-4C77-99F1-348DD4BD4F0EQ26781795-060ABC25-8E64-4563-B32D-B48A3AB066EDQ28551711-7A17B6E2-7A96-4B21-9362-23F37420EC8CQ33608997-2C70EC92-1900-41C2-86C9-9E162C1F7F53Q33857643-E1A194BC-1D0B-4541-B276-3595BF243BCFQ34208672-3457264B-3955-43D7-9D52-F2F3F9D5FAAFQ34225266-288D4246-3AFE-4BEB-A5D0-8197A9A8A60FQ34489239-C1680C70-C94A-41B9-970E-40EA77B8B8E4Q34647599-B1ED20A2-7CB8-422B-9E05-C87B6792B650Q34847029-550A2599-262B-4780-971C-67AA81302EDDQ34948124-D9524C2B-4A13-4B71-A5CA-7172EADC4584Q35026531-BA1148BB-7526-43DF-B29D-9DD11444ABD7Q35487430-02DE75D2-394D-43EB-B89B-ACBED9B8BEEAQ35535861-DFFCD374-E02B-40D5-BA29-A952E52E5D6BQ35890599-37E5E064-32DB-4A55-B83D-4F9252422B1FQ36018658-D1216817-6A94-4932-94D8-2AFE991EAFE3Q36153966-F1EC3EC7-DEAE-4C19-97CE-56875A3F4706Q36492640-0CB09027-979B-4BD6-97BB-67EF77FCF51DQ36606780-13F8529B-1222-4610-A1FE-DDB1CAD31A00Q36663686-D131254E-3CA8-45FF-AA49-1B8200E770C2Q36932959-F5D07F10-44E8-4985-B2F8-1F31C0DC8145Q36969950-CC676ACB-F71D-4722-9504-845B2A9B9BA3Q37212962-9907CB57-3522-4285-A4E3-E4C407133FAFQ37229851-2D481458-FEF6-4D0C-A83A-C9A3F051B1F1Q37255008-559A349F-DC81-42E4-8231-5527BB2660E9Q37564039-3C2DE529-6E6E-44E8-B4C4-3347E349E694Q37696029-0D8AD9B5-AEA5-4475-8CDD-DF98ECB769DDQ37738814-EDB664A3-1B5D-4984-8BAF-172CC611F543Q37760897-DC594C21-EB04-4749-AF2C-EAA6E6ADFC9DQ37762114-902728F3-E8E2-40E0-B812-55DF45D65AAAQ38219020-C6A55DAC-C9E2-41B9-B273-B53D452C0DB1Q38247981-8D203755-11FD-49D6-BCC2-C608E00F2740Q39986281-E398B5FD-8236-4AC1-94F8-A534CF0F51F3Q41435482-F2C1B622-F015-4DB3-B896-EB0B152D943DQ42131024-2767A545-4347-44BA-8DB1-27A9BF121244Q43105141-143B94F0-E9DF-416E-B99D-8B3D3EA14070Q58727285-4928539F-08A3-4DBB-A32F-577166F6A0C6
P2860
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
In vitro susceptibility of ade ...... ons to other antiviral agents.
@en
type
label
In vitro susceptibility of ade ...... ons to other antiviral agents.
@en
prefLabel
In vitro susceptibility of ade ...... ons to other antiviral agents.
@en
P2093
P1433
P1476
In vitro susceptibility of ade ...... ons to other antiviral agents.
@en
P2093
Huiling Yang
Michael Miller
Shelly Xiong
William E Delaney
Xiaoping Qi
P304
P577
2007-01-01T00:00:00Z